Tags

Type your tag names separated by a space and hit enter

Combination of solifenacin and tamsulosin may provide additional beneficial effects for ureteral stent-related symptoms-outcomes from a network meta-analysis.
World J Urol. 2019 Feb; 37(2):289-297.WJ

Abstract

PURPOSE

To systematically evaluate the different efficacy among generally used drugs for stent-related symptoms (SRS) with the method of network meta-analysis.

METHODS

A systematic search was performed in the US National Library of Medicine's life science database (Medline), Embase, the Cochrane Central Register of Controlled Trials, and the Cochrane Database for Systematic Reviews before December 2017. Analysis was performed under multivariate random-effects network model and effects of drugs were ranked with surface under the cumulative ranking (SUCRA) probabilities.

RESULTS

19 trials with 2036 patients investigating 4 different intervention including tamsulosin (Tam), alfuzosin (Alfu), solifenacin (Soli) and combination of Tam and Solif were finally included in our analysis. Tam plus Soli had the highest SUCRA on all aspects of ureteral stent symptom questionnaire: urinary symptoms (86.2%), body pain (85.0%), general health (80.5%), work performance (72.0%) and sexual performance (84.4%). Except for pain relief, Soli showed higher SUCRA than Tam or Alfu in rest respects. Tam and Alfu showed similar SUCRA on urinary symptoms (53.0 vs 48.7%) and body pain relief (61.9 vs 62.9%).

CONCLUSIONS

Tam plus Soli might be the most effective intervention for SRSs. As for monotherapy, Soli showed advantages in most respects except for pain relief compared to Tam or Alfu. Tam and Alfu showed similar efficacy on urinary symptoms and body pain relief.

Authors+Show Affiliations

Department of Urology, Institute of Urology (Laboratory of Reconstructive Urology), West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, 610041, Sichuan, People's Republic of China.Department of Urology, Institute of Urology (Laboratory of Reconstructive Urology), West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, 610041, Sichuan, People's Republic of China.Department of Urology, Institute of Urology (Laboratory of Reconstructive Urology), West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, 610041, Sichuan, People's Republic of China.Department of Urology, Institute of Urology (Laboratory of Reconstructive Urology), West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, 610041, Sichuan, People's Republic of China.Department of Urology, Institute of Urology (Laboratory of Reconstructive Urology), West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, 610041, Sichuan, People's Republic of China.Department of Urology, Institute of Urology (Laboratory of Reconstructive Urology), West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, 610041, Sichuan, People's Republic of China.Department of Urology, Institute of Urology (Laboratory of Reconstructive Urology), West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, 610041, Sichuan, People's Republic of China. wangkj@scu.edu.cn.

Pub Type(s)

Journal Article
Meta-Analysis
Systematic Review

Language

eng

PubMed ID

30030658

Citation

Jian, Zhongyu, et al. "Combination of Solifenacin and Tamsulosin May Provide Additional Beneficial Effects for Ureteral Stent-related Symptoms-outcomes From a Network Meta-analysis." World Journal of Urology, vol. 37, no. 2, 2019, pp. 289-297.
Jian Z, Chen Y, Liu Q, et al. Combination of solifenacin and tamsulosin may provide additional beneficial effects for ureteral stent-related symptoms-outcomes from a network meta-analysis. World J Urol. 2019;37(2):289-297.
Jian, Z., Chen, Y., Liu, Q., Liao, B., Yang, T., Li, H., & Wang, K. (2019). Combination of solifenacin and tamsulosin may provide additional beneficial effects for ureteral stent-related symptoms-outcomes from a network meta-analysis. World Journal of Urology, 37(2), 289-297. https://doi.org/10.1007/s00345-018-2404-6
Jian Z, et al. Combination of Solifenacin and Tamsulosin May Provide Additional Beneficial Effects for Ureteral Stent-related Symptoms-outcomes From a Network Meta-analysis. World J Urol. 2019;37(2):289-297. PubMed PMID: 30030658.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Combination of solifenacin and tamsulosin may provide additional beneficial effects for ureteral stent-related symptoms-outcomes from a network meta-analysis. AU - Jian,Zhongyu, AU - Chen,Yuntian, AU - Liu,Qinyu, AU - Liao,Banghua, AU - Yang,Tongxin, AU - Li,Hong, AU - Wang,Kunjie, Y1 - 2018/07/20/ PY - 2018/04/11/received PY - 2018/07/07/accepted PY - 2018/7/22/pubmed PY - 2019/5/29/medline PY - 2018/7/22/entrez KW - Drug therapies KW - Network meta-analysis KW - Ureteral stent-related symptoms SP - 289 EP - 297 JF - World journal of urology JO - World J Urol VL - 37 IS - 2 N2 - PURPOSE: To systematically evaluate the different efficacy among generally used drugs for stent-related symptoms (SRS) with the method of network meta-analysis. METHODS: A systematic search was performed in the US National Library of Medicine's life science database (Medline), Embase, the Cochrane Central Register of Controlled Trials, and the Cochrane Database for Systematic Reviews before December 2017. Analysis was performed under multivariate random-effects network model and effects of drugs were ranked with surface under the cumulative ranking (SUCRA) probabilities. RESULTS: 19 trials with 2036 patients investigating 4 different intervention including tamsulosin (Tam), alfuzosin (Alfu), solifenacin (Soli) and combination of Tam and Solif were finally included in our analysis. Tam plus Soli had the highest SUCRA on all aspects of ureteral stent symptom questionnaire: urinary symptoms (86.2%), body pain (85.0%), general health (80.5%), work performance (72.0%) and sexual performance (84.4%). Except for pain relief, Soli showed higher SUCRA than Tam or Alfu in rest respects. Tam and Alfu showed similar SUCRA on urinary symptoms (53.0 vs 48.7%) and body pain relief (61.9 vs 62.9%). CONCLUSIONS: Tam plus Soli might be the most effective intervention for SRSs. As for monotherapy, Soli showed advantages in most respects except for pain relief compared to Tam or Alfu. Tam and Alfu showed similar efficacy on urinary symptoms and body pain relief. SN - 1433-8726 UR - https://www.unboundmedicine.com/medline/citation/30030658/Combination_of_solifenacin_and_tamsulosin_may_provide_additional_beneficial_effects_for_ureteral_stent-related_symptoms-outcomes_from_a_network_meta-analysis L2 - https://dx.doi.org/10.1007/s00345-018-2404-6 DB - PRIME DP - Unbound Medicine ER -